Exercise to Boost Response to Checkpoint Blockade Immunotherapy

This trial is studying whether a structured exercise program can boost the effectiveness of immunotherapy (specifically checkpoint blockade drugs) in cancer patients. Participants will be randomly assigned to an exercise group or a standard care group while receiving their scheduled immunotherapy. **You may be eligible if...** - You are 18 or older - You can read and speak English - You are able to walk unaided for at least 6 minutes - You are scheduled to start immunotherapy (avelumab, cemiplimab, ipilimumab, nivolumab, or pembrolizumab) for melanoma, squamous cell skin cancer, or Merkel cell carcinoma - You are willing to follow the prescribed exercise plan and complete study forms **You may NOT be eligible if...** - You have a serious heart condition that makes exercise unsafe - You have major complications from recent surgery - You have an active contagious disease such as tuberculosis, active hepatitis B or C, HIV, or COVID-19 - You are receiving other cancer treatments alongside immunotherapy (e.g., targeted therapy) Talk to your doctor to see if this trial is right for you.